CAS 27851-29-2
:[(3R,4S,5S,6R)-3,4,5,6-tétrabenzyl-oxytétrahydropyran-2-yl]méthanol
Formule :C34H36O6
InChI :InChI=1/C34H36O6/c35-21-30-31(36-22-26-13-5-1-6-14-26)32(37-23-27-15-7-2-8-16-27)33(38-24-28-17-9-3-10-18-28)34(40-30)39-25-29-19-11-4-12-20-29/h1-20,30-35H,21-25H2/t30?,31-,32+,33+,34-/m1/s1
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
7 produits trouvés.
Benzyl 2,3,4-Tri-O-benzyl-β-D-glucopyranoside
CAS :Formule :C34H36O6Degré de pureté :min. 95.0 area%(HPLC)Couleur et forme :White to Almost white powder to crystalMasse moléculaire :540.66β-D-Glucopyranoside, phenylmethyl 2,3,4-tris-O-(phenylmethyl)-
CAS :Formule :C34H36O6Degré de pureté :95%Couleur et forme :SolidMasse moléculaire :540.6460Benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside
CAS :Benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranosideFormule :C34H36O6Degré de pureté :>98%Masse moléculaire :540.646041,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside
CAS :1,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside is a prodrug that becomes active after acetylation. It is an endogenous compound that has been shown to inhibit the synthesis of myelin and lipid peroxidation in rat brains. This drug has also been found to be effective in the treatment of amyotrophic lateral sclerosis (ALS). 1,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside is unmodified and does not have any side effects on the nervous system. It can be used for the treatment of Parkinson's disease when combined with levodopa.Formule :C34H36O6Degré de pureté :Min. 95%Couleur et forme :White Off-White PowderMasse moléculaire :540.65 g/molBENZYL 2,3,4-TRI-O-BENZYL-β-D-GLUCOPYRANOSIDE
CAS :Degré de pureté :≥98%Masse moléculaire :540.6560059Benzyl 2,3,4-Tri-O-benzyl-β-D-glucopyranoside
CAS :Produit contrôléApplications Benzyl 2,3,4-Tri-O-benzyl-β-D-glucopyranoside (cas# 27851-29-2) is a compound useful in organic synthesis.
References Wakao, M., et al.: Bioorg. Med. Chem. Lett., 18, 2499 (2008),Formule :C34H36O6Couleur et forme :NeatMasse moléculaire :540.65






